X4 Pharmaceuticals (XFOR) Capital Expenditures Growth (1y) (2018 - 2024)
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) Capital Expenditures Growth (1y) (2018 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 26.65% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 19.70% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 16.88% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 3.02% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -13.75% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | -37.81% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | -34.92% |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 42,912.50% |
| Mar 31, 2024 | 555.56% |
| Dec 31, 2023 | 2.94% |
| Sep 30, 2023 | -11.11% |
| Jun 30, 2023 | -78.95% |
| Mar 31, 2023 | -59.09% |
| Dec 31, 2022 | 161.54% |
| Sep 30, 2022 | -55.00% |
| Jun 30, 2022 | -55.81% |
| Mar 31, 2022 | -95.56% |
| Dec 31, 2021 | 101.88% |
| Sep 30, 2021 | -98.66% |
| Jun 30, 2021 | 855.56% |
| Mar 31, 2021 | -10.63% |
| Dec 31, 2020 | -931.33% |
| Sep 30, 2020 | 1,737.04% |
| Jun 30, 2020 | -10.00% |
| Sep 30, 2019 | 400.00% |
| Sep 30, 2018 | -250.00% |